$CLDX,
Celldex Therapeutics, Inc. (CLDX) Position Maintained by NJ State Employees Deferred Compensation Plan
Posted by Emily Klein on Mar 14th, 2016 // No Comments
Celldex Therapeutics logoNJ State Employees Deferred Compensation Plan continued to hold its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 100,000 shares of the biopharmaceutical company’s stock at the end of the fourth quarter. NJ State Employees Deferred Compensation Plan owned 0.10% of Celldex Therapeutics worth $1,568,000 as of its most recent SEC filing.
Several other hedge funds have also recently added to or reduced their stakes in CLDX. ProShare Advisors LLC increased its stake in Celldex Therapeutics by 10.7% in the fourth quarter. ProShare Advisors LLC now owns 93,666 shares of the biopharmaceutical company’s stock valued at $1,469,000 after buying an additional 9,072 shares in the last quarter. Columbus Circle Investors boosted its position in shares of Celldex Therapeutics by 10.5% in the fourth quarter. Columbus Circle Investors now owns 655,739 shares of the biopharmaceutical company’s stock valued at $10,282,000 after buying an additional 62,246 shares during the last quarter. Suffolk Capital Management LLC boosted its position in shares of Celldex Therapeutics by 32.4% in the fourth quarter. Suffolk Capital Management LLC now owns 167,215 shares of the biopharmaceutical company’s stock valued at $2,622,000 after buying an additional 40,906 shares during the last quarter. Oxford Asset Management boosted its position in shares of Celldex Therapeutics by 430.1% in the fourth quarter. Oxford Asset Management now owns 548,708 shares of the biopharmaceutical company’s stock valued at $8,695,000 after buying an additional 445,200 shares during the last quarter. Finally, Rhumbline Advisers boosted its position in shares of Celldex Therapeutics by 4.9% in the fourth quarter. Rhumbline Advisers now owns 108,426 shares of the biopharmaceutical company’s stock valued at $1,700,000 after buying an additional 5,110 shares during the last quarter.
Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) opened at 3.48 on Monday. Celldex Therapeutics, Inc. has a one year low of $3.42 and a one year high of $32.82. The company’s market cap is $343.49 million. The stock’s 50 day moving average price is $7.19 and its 200-day moving average price is $12.38.
Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings data on Thursday, February 25th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.02. The company had revenue of $1.80 million for the quarter, compared to analyst estimates of $0.80 million. Celldex Therapeutics’s revenue for the quarter was up 21.1% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.36) EPS. On average, analysts expect that Celldex Therapeutics, Inc. will post ($1.33) EPS for the current year.
Several brokerages have recently weighed in on CLDX. Brean Capital restated a “buy” rating and issued a $24.00 price objective on shares of Celldex Therapeutics in a report on Tuesday, March 8th. Roth Capital restated a “buy” rating on shares of Celldex Therapeutics in a report on Tuesday, March 8th. Leerink Partner cut Celldex Therapeutics from an “outperform” rating to a “market perform” rating in a report on Monday, March 7th. Leerink Swann cut Celldex Therapeutics from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $30.00 to $4.00 in a report on Monday, March 7th. Finally, Cowen and Company restated an “outperform” rating and issued a $12.00 price objective (down previously from $28.00) on shares of Celldex Therapeutics in a report on Tuesday, March 8th. Seven analysts have rated the stock with a hold rating and six have given a buy rating to the company. Celldex Therapeutics has an average rating of “Hold” and an average target price of $20.00.
Celldex Therapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases.
12 Month Chart for NASDAQ:CLDX
Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
Celldex Therapeutics, Inc. (CLDX) Position Maintained by NJ State Employees Deferred Compensation Plan
Posted by Emily Klein on Mar 14th, 2016 // No Comments
Celldex Therapeutics logoNJ State Employees Deferred Compensation Plan continued to hold its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 100,000 shares of the biopharmaceutical company’s stock at the end of the fourth quarter. NJ State Employees Deferred Compensation Plan owned 0.10% of Celldex Therapeutics worth $1,568,000 as of its most recent SEC filing.
Several other hedge funds have also recently added to or reduced their stakes in CLDX. ProShare Advisors LLC increased its stake in Celldex Therapeutics by 10.7% in the fourth quarter. ProShare Advisors LLC now owns 93,666 shares of the biopharmaceutical company’s stock valued at $1,469,000 after buying an additional 9,072 shares in the last quarter. Columbus Circle Investors boosted its position in shares of Celldex Therapeutics by 10.5% in the fourth quarter. Columbus Circle Investors now owns 655,739 shares of the biopharmaceutical company’s stock valued at $10,282,000 after buying an additional 62,246 shares during the last quarter. Suffolk Capital Management LLC boosted its position in shares of Celldex Therapeutics by 32.4% in the fourth quarter. Suffolk Capital Management LLC now owns 167,215 shares of the biopharmaceutical company’s stock valued at $2,622,000 after buying an additional 40,906 shares during the last quarter. Oxford Asset Management boosted its position in shares of Celldex Therapeutics by 430.1% in the fourth quarter. Oxford Asset Management now owns 548,708 shares of the biopharmaceutical company’s stock valued at $8,695,000 after buying an additional 445,200 shares during the last quarter. Finally, Rhumbline Advisers boosted its position in shares of Celldex Therapeutics by 4.9% in the fourth quarter. Rhumbline Advisers now owns 108,426 shares of the biopharmaceutical company’s stock valued at $1,700,000 after buying an additional 5,110 shares during the last quarter.
Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) opened at 3.48 on Monday. Celldex Therapeutics, Inc. has a one year low of $3.42 and a one year high of $32.82. The company’s market cap is $343.49 million. The stock’s 50 day moving average price is $7.19 and its 200-day moving average price is $12.38.
Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings data on Thursday, February 25th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.02. The company had revenue of $1.80 million for the quarter, compared to analyst estimates of $0.80 million. Celldex Therapeutics’s revenue for the quarter was up 21.1% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.36) EPS. On average, analysts expect that Celldex Therapeutics, Inc. will post ($1.33) EPS for the current year.
Several brokerages have recently weighed in on CLDX. Brean Capital restated a “buy” rating and issued a $24.00 price objective on shares of Celldex Therapeutics in a report on Tuesday, March 8th. Roth Capital restated a “buy” rating on shares of Celldex Therapeutics in a report on Tuesday, March 8th. Leerink Partner cut Celldex Therapeutics from an “outperform” rating to a “market perform” rating in a report on Monday, March 7th. Leerink Swann cut Celldex Therapeutics from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $30.00 to $4.00 in a report on Monday, March 7th. Finally, Cowen and Company restated an “outperform” rating and issued a $12.00 price objective (down previously from $28.00) on shares of Celldex Therapeutics in a report on Tuesday, March 8th. Seven analysts have rated the stock with a hold rating and six have given a buy rating to the company. Celldex Therapeutics has an average rating of “Hold” and an average target price of $20.00.
Celldex Therapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases.
12 Month Chart for NASDAQ:CLDX
Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
